Atypical kinetics for a series of putative dopamine antagonists to reverse the low-magnitude Ca2+ phase in the dopamine-bound D2short receptor state

P. J. Pauwels, W. Koek

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Real-time analysis of dopamine:antagonist interactions at the recombinant D2short receptor was performed by measuring time-dependent Ca2+ responses following activation of a chimeric Gαq/o protein in CHO-K1 cells. Terguride (57%), (+)-UH 232 (20%) and buspirone (16%) demonstrated dopamine-like intrinsic activity at the presumably unoccupied, dopamine-free receptor; retoxipride, pipamperone and L 741626 being silentat 1 μM. Each of the putative antagonists (1 μM) displayed a transient reversal capacity of the low-magnitude Ca2+ phase in the dopamine-bound receptor state (Erev: 68%-92% vs. 1 μM tropapride) with a t1/2 between 8.8 s and 13.9 s upon antagonist addition; this capacity was either almost fully [remoxipride, pipamperone and (+)-UH 232] or partially [buspirone (31%), terguride (45%) and L 741626 (70%)] lost upon further incubation. The biphasic reversal Ca2+ profile of these dopamine antagonists is different from previously characterised dopamine antagonists which display either full reversal of the low-magntude Ca2+ response with a fast or slow onset of action, or partial reversal stably present over the entire incubation period. The dynamic Ca2+ data strongly suggest that the dopamine D2short receptor can be blocked via multiple molecular mechanisms.

Original languageEnglish (US)
Pages (from-to)82-85
Number of pages4
JournalNaunyn-Schmiedeberg's Archives of Pharmacology
Volume365
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Keywords

  • CHO-K1 cells
  • Ca response
  • Dopamine antagonist
  • Recombinant human dopamine D receptor

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Atypical kinetics for a series of putative dopamine antagonists to reverse the low-magnitude Ca<sup>2+</sup> phase in the dopamine-bound D<sub>2short</sub> receptor state'. Together they form a unique fingerprint.

Cite this